engleski

The effects of rosuvastatin, simvastatin and fenofibrate on brain malondialdehyde in rats

Free radicals can be involved in pathogenesis of Alzheimer disease (AD). While the literature data have shown that antilipemic drugs either decrease or have not influence on malondialdehyide (MDA) level, our previous unpublished results have shown that simvastatin (SIMV) reduce MDA in rat’s brain. We decided to compare the influence of rosuvastatin (ROSU) and fenofibrate (FENO) on MDA level in the brain of normolipidemic rats and to repeat the experiment with (SIMV). Ninety male Wistar rats were divided into five control groups (saline) and five experimental groups. One experimental group was on SIMV treatment (10 mg/kg/day), two groups on ROSU treatment (5 and 10 mg/kg/day) and remaining groups on FENO treatment (30 and 50 mg/kg/day). Agents and saline were given orally for the period of 3 weeks. Animals were sacrificed with ether 24 hours after the last dose and brain samples were rinsed with saline. MDA levels were measured by HPLC-MS method (Drury JA et al, 1997). Data were analysed by Dunn’s Multiple Comparison Test. ROSU and SIMV in dose of 10 mg/kg/day decreased significantly MDA level (μmol/L) in brain of normolipidemic rats for 10% and 58% vs. control (p<0.05, mean±SD) (ROSU 10 mg vs. control: 2.549±0.2762 vs. 2.812±0.2368 ; SIMV 10 mg vs. control: 1.112±0.2306 vs. 2.664±0.2044), while lower dose of ROSU and FENO didn’t influence MDA level vs. control. Higher dose of FENO indicated a decrease of MDA by 21% in comparison with control: FENO 50 mg vs. control: 2.282±0.2012 vs. 2.891±1.0181). Our results have shown that rosuvastatin, simvastatin and fenofibrat decrease MDA level in brain of normolipidemic rats. As well, our previous results obtained with simvastatin are confirmed. According to these results we have suggested that protective effect of antilipemic drugs against AD may be the consequence of their antioxidative action.

statins; fenofibrate; malondialdehyde; brain; rat

nije evidentirano